Anixa Biosciences, Inc.
ANIX
NASDAQ·Healthcare·Biotechnology·Mkt cap $104.5M
$3.07
▲ +0.66%
P/E
-9.75
Mkt Cap
$104.5M
52-Wk Range
$2.32–$5.46
52-Week Range
$2.32 - $5.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 3.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary chimeric endocrine receptor T-cell technology platform
- Diversified pipeline addressing multiple cancer types and infectious diseases
- Strategic partnerships with established biotech firms like MolGenie GmbH
- Focus on high-unmet-need therapeutic areas with significant market opportunities
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Advancement of CAR-T therapies through clinical development stages
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+24.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ANIX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 9, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.08.
Reported EPS · last 4Q
Q1 26
-$0.08
Q4 25
-$0.08
Q3 25
-$0.07
Q2 25
-$0.09
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: D. Boral Capital · Apr 8, 2026
vs Industry
How ANIX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related